Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2, 2004. The document serves as a correction to previous Regulatory News Service (RNS) announcements regarding the date of the Annual General Meeting (AGM) and details specific share repurchase activities executed on March 2, 2004.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share buyback transactions:
- Transaction 1: 900,000 ordinary shares purchased for cancellation at 1133.243p per share.
- Transaction 2: 875,000 ordinary shares purchased for cancellation at 1128.5487p per share.
Material Changes
The primary material change noted is the correction of the AGM date previously reported as May 23, 2003, to the correct date of May 19, 2003. Additionally, the filing reports the execution of share repurchases under the authority granted at that corrected AGM date.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly an administrative update correcting a date error and reporting completed share buybacks.
Investor Verification Checklist
- Verify the corrected Annual General Meeting date of May 19, 2003, in historical records.
- Confirm the total number of shares repurchased for cancellation on March 2, 2004 (1,775,000 shares).
- Check the weighted average price paid for the repurchased shares against the market price on the transaction date.
- Review the remaining share repurchase authority granted at the May 19, 2003 AGM to determine if further buybacks are authorized.